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Background: Human leukocyte antigen (HLA)-G is a nonclassical class I antigen with immunomodulatory roles
including up-regulation of suppressor T regulatory lymphocytes. HLA-G was recently identified as an asthma
susceptibility gene, and expression of a soluble isoform, HLA-G5, has been demonstrated in human airway
epithelium. Increased presence of HLA-G5 has been demonstrated in bronchoalveolar lavage fluid recovered from
patients with mild asthma; this suggests a role for this isoform in modulating airway inflammation though the
mechanisms by which this occurs is unclear. Airway inflammation associated with Th2 cytokines such as IL-4 and
IL-13 is a principal feature of asthma, but whether these cytokines elicit expression of HLA-G is not known.
Methods: We examined gene and protein expression of both soluble (G5) and membrane-bound (G1) HLA-G
isoforms in primary differentiated human airway epithelial cells collected from normal lungs and grown in air-liquid
interface culture. Cells were treated with up to 10 ng/ml of either IL-4, IL-5, or IL-13, or 100 ng/ml of the
immunomodulatory cytokine IL-10, or 10,000 U/ml of the Th1-associated cytokine interferon-beta, for 24 hr, after
which RNA was isolated for evaluation by quantitative PCR and protein was collected for Western blot analysis.
Results: HLA-G5 but not G1 was present in dAEC as demonstrated by quantitative PCR, western blot and confocal
microscopy. Neither G5 nor G1 expression was increased by the Th2-associated cytokines IL-4, IL-5 or IL-13 over
24 hr, nor after treatment with IL-10, but was increased 4.5 ± 1.4 fold after treatment with 10,000 U/ml interferon-
beta.
Conclusions: These data demonstrate the constitutive expression of a T lymphocyte regulatory molecule in
differentiated human airway epithelial cells that is not modulated by Th2-associated cytokines.
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Asthma is one of the most common chronic medical dis-
orders in the Western world with an increasing prevalence
and significant morbidity [1,2]. T lymphocytes commonly
infiltrate into the mucosa of asthmatic airways [3,4], and
environmental exposures may trigger an “over-zealous” re-
sponse of airway-resident T helper 2 (Th2)-subclass CD4+
lymphocytes [3-6]. Fluid recovered by bronchoalveolar
lavage from asthmatic airways is enriched in interleukin* Correspondence: swhite@medicine.bsd.uchicago.edu
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reproduction in any medium, provided the or(IL)-4, IL-5, IL-13 and granulocyte-macrophage colony
stimulating factor (GM-CSF) but not IFN-γ [5], indicating
the presence of Th2 subclass CD4+ lymphocytes. Epithe-
lial cells stimulated with either IL-4 or IL-13 express
cytokines and chemokines that trigger and maintain
airway inflammation [7-11]. Both IL-4 and IL-13 elicit
changes in epithelial structure, morphology and differ-
entiation that contribute to both airway inflammation
and remodeling [12-14].
Human leukocyte antigen-G (HLA-G) is a non-classical,
class Ib, major histocompatibility complex antigen [15].
HLA-G differs from classical Ia molecules because of its
limited polymorphism in the coding region and a some-
what restricted tissue distribution. Alternative splicingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that dimerize with β2-microglobulin (β2m) light chains
similar to other class I molecules [16,17].
Originally considered a pregnancy-specific HLA with a
critical role in maintaining immune tolerance toward the
allogenic fetus [18-20], it is now appreciated that HLA-G
is expressed in adult tissues [21]. Recent studies in
asthmatic families and in a birth cohort at high risk for
developing asthma suggest a role for HLA-G in asthma
susceptibility [22,23]. Associations in genetic variations in
the promoter region [22] and in a microRNA target site in
the 3’UTR [23] of HLA-G suggested that dysregulated ex-
pression may contribute to asthma pathogenesis [22,23].
A soluble protein isoform of HLA-G, HLA-G5, is present
in airway epithelial cells in vivo [22]. Increased circulating
levels of G5 was reported in two studies of children with
atopic asthma [24,25], and G5 was present in greater
abundance in bronchoalveolar lavage fluid collected from
subjects with mild, persistent asthma compared to control
subjects [26].
HLA-G is a ligand for the leukocyte Ig-like receptor
(LILR) B1 (also referred to as inhibitory receptor Ig-like
transcript (ILT)2, CD85j), expressed by human NK cells,
monocytes, T cells, B cells and dendritic cells [27], and
the myeloid-specific LILRB2 (ILT4, CD85d) receptor
[28] with high specificity [29]. In vitro data indicate that
HLA-G inhibits both NK cell and CD8+ T cell mediated
cytolysis [30], suppresses CD4+ T cell alloproliferative
responses [31], and induces apoptosis of CD8+ T cells
[32]. Moreover, HLA-G can down-regulate the expres-
sion of CD4 and CD8 on allostimulated T cells [33], and
promote maternal immune cell cytokine release toward
a Th2-skewed profile [34]. HLA-G then may be an at-
tractive candidate molecule for modulating specific T cell
profiles that are important in asthma. Further, HLA-G
production may in turn be regulated by the pleiotropic,
immunoregulatory cytokine IL-10 which may in the con-
text of asthma further regulate T cell profiles and function.
IL-10 is generally a suppressive cytokine that inhibits in-
flammatory mediator expression and suppresses selected
T cell activation pathways. The production of both IL-10
and sHLA-G in peripheral blood mononuclear cells
(PBMCs) collected from subjects with asthma and stimu-
lated with lipopolysaccharide (LPS) is lower than that seen
in similarly-treated cells collected from normal subjects
[35], and addition of exogenous IL-10 to asthmatic PBMCs
restored sHLA-G production to concentrations seen in
normal PBMCs after LPS stimulation [36].
Given the multiple effects of Th2-associated cytokines
on airway inflammation [7-11] and remodeling [12-14],
it was unclear whether IL-4 and IL-13 would stimulate
HLA-G expression and abundance in airway epithelial
cells that would be counter-regulatory to inflammation,
or whether, as promoters of airway inflammation, IL-4and IL-13 would actually downregulate HLA-G expres-
sion. Further, IL-10 and the IL-10 promoter region [37]
contain polymorphisms that are associated with asthma
susceptibility, though this is disputed in other studies
[38], and serum IL-10 concentrations are lower in chil-
dren with atopic asthma compared to normal children
[25]. Thus decreased production of IL-10 in asthma
might in turn lead to changes in HLA-G expression. To
test these hypotheses, we examined HLA-G expression
and abundance in a culture model of differentiated air-
way epithelial cells (dAEC) that has proven to be useful
in examining epithelial cell function. We then examined
whether the Th2-associated cytokines IL-4, IL-5 or
IL-13, the Th1-associated interferon-beta (IFN-β), or the
immunoregulatory cytokine IL-10 regulated HLA-G ex-
pression. We demonstrate the constitutive expression of
soluble G5 in differentiated AEC, and that IFN-β but




Antibodies directed against HLA-G (4H84 clone), HLA-
G5 (5A6G7 and MEM-G/9) or HLA-G1 (01 G) were
obtained from Exbio, Inc. (Prague, Czech Republic).
Antibodies directed against β-tubulin were obtained
from Abcam, Inc. (Cambridge, MA). Antibodies directed
against IL-10R1 and IL-10R2 were obtained from R&D
Systems, Inc. (Minneapolis, MN). Antibodies directed
against IL-10R1, cytokeratin-5 (CK5) and MUC5AC
were obtained from Santa Cruz Biotechnologies, Inc.
(Santa Cruz, CA). All secondary antibodies were
obtained from Invitrogen, Inc. (Carlsbad, CA). All
other reagents were obtained from Sigma-Aldrich,
Inc. (St. Louis, MO).
Cell culture
We have described previously methods for collection
of primary human airway epithelial cells from donated
lungs and their culture in air-liquid interface (ALI) for
3 wk to generate dAEC [39]. These cells develop charac-
teristics of differentiated cells with appearance of cilia,
secretion of mucins, and the presence of markers such
as β-tubulin (for ciliated cells) and MUC5AC (for goblet
cells) [39,40]. Cells were collected from lungs provided
by the Regional Organ Bank of Illinois (Elmhurst, IL).
Confocal microscopy
We have described this method previously [39,40]. Cells
were stained with two primary antibodies. The first was
directed against either cytokeratin 5 (CK5) (mouse anti-
human, sc-32721, or goat anti-human, sc-17090) to
mark basal cells [41,42], MUC5AC (rabbit anti-human,


















































e) N = 7N = 7
1 2 3 4 5 6 JAR JEG3
sHLA-G
-actin
Figure 1 Demonstration of HLA-G in primary dAEC grown in ALI culture. A. Expression of HLA-G as demonstrated by qPCR. One sample
from each subject was tested in triplicate and normalized to 18S-RNA expression. A positive control cell line (JEG-3) analyzed at the same time is
shown for reference. B. Protein expression of HLA-G as demonstrated by western blot. Whole cell lysates collected from six different dAEC
cultures were resolved using the 4H84 mAb that binds both, and cannot distinguish between, the soluble G5 and membrane bound G1 isoforms.
A single band at ~ 39 kD consistent with HLA-G is demonstrated. A negative control, the JAR choriocarcinoma cell line that does not express
HLA-G, and a positive control, the JEG3 choriocarcinoma cell line, are shown.
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goat anti-human, ab21057) to mark ciliated cells [45]. The
second was directed against soluble G5 (MEM-G/9 or
5A6G7 mAbs). Background was calculated from images
collected after staining that omitted the primary antibody;
this was subtracted from all images using ImageJ (Wayne
Rasband, National Institutes of Health, Bethesda, MD).
For each z-stack generated, x,y slices were selected start-
ing from the membrane on which cells were grown, and
progressing to the top of the cells; these slices then were
combined using a maximum intensity protocol (ImageJ)
to generate final images. At least three separate experi-
ments were done for each set of antibodies used, and rep-
resentative images were selected.Quantitative real-time polymerase chain reaction (qPCR)
Total RNA was isolated from cells using TRI Reagent
(Sigma) following the manufacturer’s protocol. Samples
were treated with DNase I (Ambion, Austin, TX). Total
RNA was reverse transcribed using random primers and
Superscript II reverse transcriptase (Invitrogen, Carlsbad,
CA). qPCR was performed using Platinum SYBR Green
qPCR SuperMix-UDG with ROX (Invitrogen). Either
primers to amplify all HLA-G isoforms (pan-G, Forward:5’-CTGACCGAGACCTGGGCGGGCT-3’; Reverse: 5’-
GGCTCCATCCTCGGACACGCCGA-3’), or isoform-
specific primers to amplify either HLA-G5 (Forward:
5’-TGCTGCAGCGCGCGGA-;3’;Reverse: 5’-GGCCTCA
CCACCGACCCTGTT-3’) or HLA-G1 (Forward: 5’-GC
TGCAGCGCGCGGAC-3’; Reverse: 5’-TGGTGGGCAG
GGAAGACTGCTT-3’) were used. cDNA samples were
tested in triplicate and normalized to 18S-sRNA expres-
sion, calculated using comparative cycle-time ratios. In
some experiments the JEG-3 choriocarcinoma cell line
was used as a positive control for HLA-G expression.Western blot analysis
Densitometry was done using ImageJ software for both
HLA-G and β-actin blots; the ratio of HLA-G blot density
to β-actin blot density reflected the relative abundance in
each lysate, as previously described [40,46].Data analysis
Data are expressed as mean ± SEM. Differences were
examined by analysis of variance; when significant differ-
ences were found, post-hoc analysis was done using
Fisher’s protected least significant difference test. Differ-
ences were considered significant when P < 0.05.
Figure 2 Presence of soluble HLA-G5 and membrane-bound HLA-G1 in dAEC by confocal microscopy. Cells were labeled using the
5A6G7 antibody for G5 (A - E) or the 01G antibody for G1 (F - J) (green in each image), and nuclei were counter-stained with Hoechst 33258
(blue). The negative control cell line JAR (A,F) and positive control cell line JEG-3 (B,G) are shown. Epithelial cells were also labeled for cytokeratin
5 (C,H), MUC5AC (D,I) or β-tubulin (E,J) (red in each image). Yellow label represents the overlap of both G5/G1 and the cell subtype marker.
Background control fluorescence for each color in each image was subtracted. Images representative of 3 experiments. Bar in (E), 10 μm for all
images.
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HLA-G is expressed in dAEC
We first examined the expression of HLA-G in primary
dAEC grown in ALI culture. RNA collected from dAEC
grown in ALI culture × 3 wk was examined for the ex-
pression of G1 and G5 using qPCR. Both isoforms wereexpressed in dAEC (Figure 1A). We then examined
whether gene expression translated into protein expres-
sion. Whole cell lysates collected from dAEC grown in
ALI culture × 3 wk were resolved by Western blot.
Using the 4H84 mAb that recognizes the soluble G5 and
a shed G1 HLA-G, a single band at ~39 kD consistent





































































































































Figure 3 Expression of HLA-G after treatment with IL-4, IL-5 or IL-13 treatment as demonstrated by qPCR. dAEC were treated with
0.1 - 10 ng/ml of each cytokine, or 10,000 U/ml of IFN-β as a positive control, for 24 hr, after which RNA expression was examined by qPCR using
G5-specific primers. For experiments in which cells were treated with a Th2-associated cytokine, expression of eotaxin-3 was measured as a
positive control of response. N = 6 experiments each for IL-13 and IL-4, 4 experiments for IL-5 and 8 experiments for IFN-β. *, P < 0.05 vs no
treatment.
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ence of G1 protein could not be ascertained separately
by western blot as the only antibody specific for this iso-
form (01 G) was not suitable for western blot analysis in
preliminary experiments (data not shown). These data
demonstrated both G1 and G5 gene expression and sig-
nificant sHLA-G protein expression in dAEC.
To characterize the localization of G5 by confocal mi-
croscopy we used the 5A6G7 mAb, which targets epi-
topes in the translated intron 4 sequence of this soluble
isoform, to label dAEC followed by confocal microscopy.
The choriocarcinoma cell lines JAR and JEG3 were used
as negative and positive controls, respectively. G5 was
localized to basal and goblet cells of dAEC, whereas
ciliated columnar cells had somewhat less abundance
(Figure 2A-E). We then examined whether membrane-
bound G1 was present using the 01 G mAb. Modest G1
localization could be demonstrated in both basal and gob-
let cells, and none in ciliated columnar cells (Figure 2F-J).
Effect of Th2-associated cytokines on HLA-G gene and
protein expression
We first examined whether treatment of dAEC with IL-4,
IL-5 or IL-13 would elicit HLA-G5 expression. Cells were
treated with 0.1 - 10 ng/ml each cytokine, or 10,000 U/mlIFN-β as a positive control [47,48], for 24 hr. There
was no clear concentration-response to any of the Th2-
associated cytokines using either the G5 specific (Figure 3)
or pan-G primers (data not shown), though IFN-β treat-
ment elicited significant HLA-G5 expression, and both
IL-4 and IL-13 increased eotaxin-3 expression [49,50], as
expected. Similarly, HLA-G protein expression did not
increase significantly following treatment with IL-4 over
24 hr (Figure 4). Treatment with IL-13 elicited increased
protein expression at the highest concentration used,
10 ng/ml (Figure 4), but this was not matched by a
change in G5 gene expression for the same concentra-
tion of IL-13 (Figure 3). These data suggested that no
Th2-associated cytokine increased expression of the
constitutively-expressed HLA-G.
Effect of IL-10 on HLA-G gene and protein expression
There is controversy over the presence of IL-10 receptor
subunits in airway epithelium: one study examined the
presence of the IL-10R1 (also IL-10Rα) subunit, respon-
sible for the specific binding of IL-10, in freshly-collected
bronchial epithelial cells and in the BEAS-2B and
16HBE14o- cell lines, demonstrating the absence of this
subunit [51]. The IL-10R2 (also IL-10Rβ), responsible for










































































Figure 4 Protein expression of HLA-G after treatment with IL-4, IL-5 or IL-13 treatment as demonstrated by western blot. dAEC were
treated with 0.1 - 10 ng/ml of each cytokine, or 10,000 U/ml of IFN-β as a positive control, for 24 hr, after which whole cell lysates were resolved
using the 4H84 antibody. Densitometry was done for each blot and normalized to control. N = 5 experiments each for IL-13 and IL-5, and
4 experiments each for IL-4 and IFN-β. *, P < 0.05 vs no treatment.
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factors [52], is ubiquitously expressed and associated not
only with IL-10R1 but with other receptor units such as
IL-22R and IL-26. We first examined whether IL-10R1 and
IL-10R2 were present in normal human airways. Using
immunoperoxidase-based staining methods, we demon-
strated the presence of both the R1 and R2 subunits reliably
in each airway, the latter as expected (Figure 5). We then
examined whether these subunits were present in dAEC.
Lysates from dAEC grown from six separate human air-
ways were examined for the presence of R1 and R2 by
Western blot. As shown in Figure 6A, the R2 subunit was
expressed as expected, while R1 subunit protein expression
was present in lower quantity. We then asked whether the
combined IL-10 receptor was functional. To test this, we
examined the phosphorylation of the potential downstreamsignaling protein STAT3 which is activated following
IL-10 treatment in macrophages [53-55]. Cells were
treated for up to 4 hr with 100 ng/ml of IL-10, after which
whole cell lysates were resolved by Western blot. As
shown in Figure 6B, there was no STAT3 phosphorylation.
As IL-10 may also elicit phosphorylation of STAT1
[56,57], we examined phosphorylation of this transcription
factor in the same lysates. No phosphorylation was seen
(Figure 6B). Finally, we asked whether IL-10 treatment
would elicit HLA-G5 expression. In these experiments,
cells were treated for 24 hr with 1–100 ng/ml IL-10 or
with 10,000 U/ml IFN-β as a positive control. As with
treatment with either IL-4 or IL-13, there was no clear
concentration response to IL-10 (Figure 6C), and the
response to IL-10 was substantially less than that seen
with IFN-β. These data suggested that the IL-10 receptor
Figure 5 Demonstration of IL-10 receptors in human airways obtained from two normal subjects (A, B, E, F), and normal human
thymus (C, D, G, H) as a control, using the AF-274 antibody for IL-10R1 (A - D) and MAB874 antibody for IL-10R2 (E - H). Representative
of 3 experiments. Bar, 100 μm for all images.
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does not elicit HLA-G expression.
Discussion
We demonstrate that HLA-G is expressed by differen-
tiated airway epithelial cells in culture. Both G1 and G5
transcripts were demonstrated by qPCR, and soluble G5
and very modest membrane-bound G1 protein expres-
sion, were demonstrated by confocal microscopy. These
data corroborate the finding of HLA-G in normal and
asthmatic airways in vivo [22,26] and thus provide a use-
ful model for studies of regulation and secretion. Fur-
ther, we demonstrate that the Th2-associated cytokinesIL-13, IL-4, and IL-5, and the immunoregulatory cyto-
kine IL-10, do not regulate the expression of HLA-G in
dAEC.
Epithelial cell secretion of HLA-G may have a role in
regulating inflammation in asthmatic airways. Soluble
isoforms of HLA-G secreted either into the airway lumen
or into the local circulation may have a paracrine role in
down-regulating inflammatory cells within airways, and in
extending its influence beyond the epithelial layer where it
can directly contact lymphocytes and dendritic cells in
and near the mucosa. Although there is no direct evidence
yet for this hypothesis in asthma, in other contexts HLA-G





































Figure 6 A. Protein expression of six separate dAEC cultures
resolved for IL-10R1 and IL-10R2. Lane loading controls resolved
for β-actin are shown. B. Phosphorylation of STAT3 in dAEC after
treatment with 100 ng/ml IL-10 for up to 4 hr. Lane loading controls
resolved for GAPDH are shown. Representative of 3 experiments.
C. Expression of HLA-G after treatment with IL-10 treatment as
demonstrated by qPCR. dAEC were treated with 1–100 ng/ml of
IL-10, or 10,000 U/ml of IFN-β as a positive control, for 24 hr, after
which RNA expression was examined by qPCR using G5-specific
primers. N = 5 experiments. *, P < 0.02 vs no treatment.
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CD4+CD25+FoxP3+ regulatory T cells [58] that can sup-
press cells that participate in airway inflammation [59].
We have recently demonstrated increased presence of
soluble HLA-G in bronchoalveolar lavage fluid recovered
from subjects with mild asthma versus control, non-
asthmatic subjects [26]; this may represent on-going
attempts to suppress (incompletely or unsuccessfully)
airway inflammation.
Because of this one could hypothesize that Th2-
associated cytokines, demonstrated in increased abun-
dance in asthmatic airways, would regulate HLA-G
expression and abundance in airway epithelial cells that
would in turn down-regulate certain aspects of airway
inflammation would be counter-productive. The counter-
hypothesis is that IL-4 and IL-13 drive airway inflamma-
tion and thus would not stimulate a counter-regulatory
mediator such as HLA-G. The latter is correct: in our
study, no Th2-associated cytokine stimulated HLA-G
expression.
The overall role of Th2-associated cytokines in air-
way inflammation is clearly context-specific. Effector
mechanisms by which these cytokines may defend the
host appropriately (e.g., against infection) are the same
that cause inappropriate or prolonged inflammation.
Stimulation of AEC by IL-4 elicits production of several
cytokines and chemokines [60-62] that contribute to air-
way inflammation in asthma, yet IL-4 also stimulates AEC
migration, a pro-reparative process [40]. Stimulation of
AEC by IL-13 elicits cytokine expression [61,62] as well
as mucoid metaplasia [14,63], both of which are pro-
inflammatory processes.
Our data also show that the IL-10R1 receptor subunit
is expressed at low concentration in both airway epithe-
lium in situ and in our dAEC culture model, and stand
in contrast to the observations of Lim et al. [51]. How-
ever, despite the presence of both receptor subunits,
treatment of dAEC with IL-10 did not elicit either
STAT3 or STAT1 phosphorylation and thus, not sur-
prisingly, we were unable to demonstrate significant
HLA-G5 expression in response to this cytokine. Our
data suggest that in contrast to expression seen in
macrophages [64], IL-10 does not stimulate HLA-G ex-
pression in airway epithelial cells.
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model, important influences on HLA-G expression may
be absent, including local and circulating factors and the
influence of cells beneath the basement membrane such
as fibroblasts. Thus, the response to Th2-associated cyto-
kines in the intact human airway may be different. How-
ever, the use of ALI culture permits examination of
cytokine influences in isolation. Future experiments can
examine the role of paracrine and circulating factors
added to this system. HLA-G expression may also change
as a function of disease state and inflammation in airways.
Our experiments utilized cells collected from normal sub-
jects, and it is possible that asthmatic epithelium may
respond differently, either in a culture system or in the
intact, inflamed airway. Careful comparison and correl-
ation then will be required to understand specific receptor
expression changes in a developing or repairing epithe-
lium in vivo.
In conclusion, our study demonstrates the presence of
HLA-G in differentiated airway epithelium in culture and
its lack of regulation by Th2-associated cytokines such as
IL-4 and IL-13 and by the immunomodulatory cytokine
IL-10. While the role of HLA-G in airway inflammation
and asthma remains to be defined, its presence, particu-
larly in greater abundance in asthmatic airways (54) and
in plasma of asthmatic subjects [24,25], suggests that epi-
thelial cell expression may be of importance in airway
inflammation.
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